Global drugmakers operating in Russia will be able to label their drugs directly at customs warehouses in Russia, which will allow them to save on costs and facilitate imports of many of foreign drugs to the Russian market.
That has been recently approved by Russia’s Prime Minister Mikhail Mishustin, reports The Pharma Letter’s local correspondent. The introduction of the measure was part of state efforts for the launch of the all-Russian system of drug labeling.
Starting from July 1 of the current year, all the drugs produced in Russia must be labeled with Data Matrix codes, which means that information about their movement in the retail network will be recorded in the Russian Federal State Information System for Monitoring the Movement of Drugs.
In addition, thanks to the system Russian regulators will be able to quickly block the supplies of low-quality and counterfeit drugs in the Russian market.
Analysts expect that the introduction of labeling practice will contribute to the decline of prices for drugs in the domestic market and simplify operations of both domestic and foreign drugmakers in Russia.
Russia to launch its own production of drugs against rare diseases
Meantime, the Russian government, together with the national Parliament, plans to create conditions for the more active development of drugs for orphan diseases in the country, according to recent statements, made by Leonid Ogul, Deputy Chairman of the Committee on Health of the Russian national Parliament (State Duma).
According to Mr Ogul and some leading Russian analysts in the field of pharmaceutics, Russia has never had its own fully-fledged production of such drugs, which is mainly due to the limited market for them in Russia and high costs, associated with the development and production of such drugs.
However, there is a possibility the situation may change already in the short-term, as the Russian government is considering forming a centralized long-term state order, that will regulate the development and production of domestic analogues of orphan drugs, the majority of which are still imported to Russia.
At present the range of such drugs available in the Russian market exceeds 30 drugs, of which only a few are produced within the country. The lack of production of such drugs is usually associated with interruptions of their supplies to local patients who need them.
Still, as part of state plans, the placement of orders will contribute to the solution of the existing problem.
Implementation of these plans will be also part of recently declared initiative of Russia’s President Vladimir Putin to reduce Russia’s dependence on the imports of drugs, which are designed for the treatment of rare diseases.
As part of these plans, Mr Putin proposed to raise the personal income tax rate from 13% to 15% for taxpayers with incomes above 5 million roubles ($68,000) a year.
It is planned these additional funds will be allocated for the design of new drugs for the treatment of children with rare diseases, as well as purchases of such drugs in abroad.